Skip to main content
NCBI home page
Protein & Cell logoLink to Protein & Cell
. 2011 Oct 6;2(9):699–703. doi: 10.1007/s13238-011-1089-z

CUEDC2: an emerging key player in inflammation and tumorigenesis

Jianghong Man 1, Xuemin Zhang 1,✉
PMCID: PMC4875262  PMID: 21976060

Abstract

CUE domain-containing 2 (CUEDC2) is a protein involved in the regulation of the cell cycle, inflammation, and tumorigenesis and is highly expressed in many types of tumors. CUEDC2 is phosphorylated by Cdk1 during mitosis and promotes the release of anaphase-promoting complex or cyclosome (APC/C) from checkpoint inhibition. CUEDC2 is also known to interact with IkB kinase α (IKKα) and IKKβ and has an inhibitory role in the activation of transcription factor nuclear factor-κB. Moreover, CUEDC2 plays an important role in downregulating the expression of hormone receptors estrogen receptor-α and progesterone receptor, thereby impairing the responsiveness of breast cancer to endocrine therapies. In this review, current knowledge on the multi-functions of CUEDC2 in normal processes and tumorigenesis are discussed and summarized.

Keywords: CUEDC2, inflammation, cell cycle, nuclear factor-κB, tumorigenesis

References

  1. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15:425–430. doi: 10.1158/1078-0432.CCR-08-0149. [DOI] [PubMed] [Google Scholar]
  2. Arpino G., Wiechmann L., Osborne C.K., Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29:217–233. doi: 10.1210/er.2006-0045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baselga J., Norton L. Focus on breast cancer. Cancer Cell. 2002;1:319–322. doi: 10.1016/S1535-6108(02)00066-1. [DOI] [PubMed] [Google Scholar]
  4. Bollen M., Peti W., Ragusa M.J., Beullens M. The extended PP1 toolkit: designed to create specificity. Trends Biochem Sci. 2010;35:450–458. doi: 10.1016/j.tibs.2010.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634–1635. doi: 10.1126/science.1071924. [DOI] [PubMed] [Google Scholar]
  6. Cui J., Zhu L., Xia X., Wang H.Y., Legras X., Hong J., Ji J., Shen P., Zheng S., Chen Z.J., et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell. 2010;141:483–496. doi: 10.1016/j.cell.2010.03.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Donaldson K.M., Yin H., Gekakis N., Supek F., Joazeiro C.A. Ubiquitin signals protein trafficking via interaction with a novel ubiquitin binding domain in the membrane fusion regulator, Vps9p. Curr Biol. 2003;13:258–262. doi: 10.1016/S0960-9822(03)00043-5. [DOI] [PubMed] [Google Scholar]
  8. Gao Y.F., Li T., Chang Y., Wang Y.B., Zhang W.N., Li W.H., He K., Mu R., Zhen C., Man J.H., et al. Cdk1-phosphorylated CUEDC2 promotes spindle checkpoint inactivation and chromosomal instability. Nat Cell Biol. 2011;13:924–933. doi: 10.1038/ncb2287. [DOI] [PubMed] [Google Scholar]
  9. Gown A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21:S8–S15. doi: 10.1038/modpathol.2008.34. [DOI] [PubMed] [Google Scholar]
  10. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L. J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–296. doi: 10.1016/j.cell.2004.07.013. [DOI] [PubMed] [Google Scholar]
  11. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899. doi: 10.1016/j.cell.2010.01.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Häcker, H., and Karin, M. (2006). Regulation and function of IKK and IKK-related kinases. Sci STKE 2006, re13. [DOI] [PubMed]
  13. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000;100:57–70. doi: 10.1016/S0092-8674(00)81683-9. [DOI] [PubMed] [Google Scholar]
  14. Hsu H., Huang J., Shu H.B., Baichwal V., Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996;4:387–396. doi: 10.1016/S1074-7613(00)80252-6. [DOI] [PubMed] [Google Scholar]
  15. Huang Q., Yang J., Lin Y., Walker C., Cheng J., Liu Z.G., Su B. Differential regulation of interleukin 1 receptor and Tolllike receptor signaling by MEKK3. Nat Immunol. 2004;5:98–103. doi: 10.1038/ni1014. [DOI] [PubMed] [Google Scholar]
  16. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–436. doi: 10.1038/nature04870. [DOI] [PubMed] [Google Scholar]
  17. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621–663. doi: 10.1146/annurev.immunol.18.1.621. [DOI] [PubMed] [Google Scholar]
  18. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–759. doi: 10.1038/nri1703. [DOI] [PubMed] [Google Scholar]
  19. Li H.Y., Liu H., Wang C.H., Zhang J.Y., Man J.H., Gao Y.F., Zhang P.J., Li W.H., Zhao J., Pan X., et al. Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. Nat Immunol. 2008;9:533–541. doi: 10.1038/ni.1600. [DOI] [PubMed] [Google Scholar]
  20. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121:977–990. doi: 10.1016/j.cell.2005.04.014. [DOI] [PubMed] [Google Scholar]
  21. Maniatis T. A ubiquitin ligase complex essential for the NFkappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 1999;13:505–510. doi: 10.1101/gad.13.5.505. [DOI] [PubMed] [Google Scholar]
  22. Mantovani A., Allavena P., Sica A., Balkwill F. Cancerrelated inflammation. Nature. 2008;454:436–444. doi: 10.1038/nature07205. [DOI] [PubMed] [Google Scholar]
  23. Minton K. Stopping before the damage is done. Nat Rev Immunol. 2008;8:372–379. doi: 10.1038/nri2296. [DOI] [PubMed] [Google Scholar]
  24. Morgan D.O. Regulation of the APC and the exit from mitosis. Nat Cell Biol. 1999;1:E47–E53. doi: 10.1038/10039. [DOI] [PubMed] [Google Scholar]
  25. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9:631–643. doi: 10.1038/nrc2713. [DOI] [PubMed] [Google Scholar]
  26. Nakano H., Shindo M., Sakon S., Nishinaka S., Mihara M., Yagita H., Okumura K. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaBinducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A. 1998;95:3537–3542. doi: 10.1073/pnas.95.7.3537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2:21–32. doi: 10.1038/35048096. [DOI] [PubMed] [Google Scholar]
  28. Normanno N., Di Maio M., De Maio E., De Luca A., de Matteis A., Giordano A., Perrone F., the NCI-Naple Breast Cancer Group Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 2005;12:721–747. doi: 10.1677/erc.1.00857. [DOI] [PubMed] [Google Scholar]
  29. Page A.M., Hieter P. The anaphase-promoting complex: new subunits and regulators. Annu Rev Biochem. 1999;68:583–609. doi: 10.1146/annurev.biochem.68.1.583. [DOI] [PubMed] [Google Scholar]
  30. Pan X., Zhou T., Tai Y.H., Wang C., Zhao J., Cao Y., Chen Y., Zhang P.J., Yu M., Zhen C., et al. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med. 2011;17:708–714. doi: 10.1038/nm.2369. [DOI] [PubMed] [Google Scholar]
  31. Peters J.M. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol. 2006;7:644–656. doi: 10.1038/nrm1988. [DOI] [PubMed] [Google Scholar]
  32. Pines J., Rieder C.L. Re-staging mitosis: a contemporary view of mitotic progression. Nat Cell Biol. 2001;3:E3–E6. doi: 10.1038/35050676. [DOI] [PubMed] [Google Scholar]
  33. Renner F., Schmitz M.L. Autoregulatory feedback loops terminating the NF-kappaB response. Trends Biochem Sci. 2009;34:128–135. doi: 10.1016/j.tibs.2008.12.003. [DOI] [PubMed] [Google Scholar]
  34. Schvartzman J.M., Sotillo R., Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer. 2010;10:102–115. doi: 10.1038/nrc2781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Shih S.C., Prag G., Francis S.A., Sutanto M.A., Hurley J.H., Hicke L. A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain. EMBO J. 2003;22:1273–1281. doi: 10.1093/emboj/cdg140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sullivan M., Morgan D.O. Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol. 2007;8:894–903. doi: 10.1038/nrm2276. [DOI] [PubMed] [Google Scholar]
  37. Visintin R., Prinz S., Amon A. CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. Science. 1997;278:460–463. doi: 10.1126/science.278.5337.460. [DOI] [PubMed] [Google Scholar]
  38. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65. doi: 10.1038/sj.cdd.4401189. [DOI] [PubMed] [Google Scholar]
  39. Weaver B.A., Cleveland D.W. The aneuploidy paradox in cell growth and tumorigenesis. Cancer Cell. 2008;14:431–433. doi: 10.1016/j.ccr.2008.11.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., Huso D.L., Brancati F.L., Wick E., McAllister F., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016–1022. doi: 10.1038/nm.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Yamashita H. Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol. 2008;13:380–383. doi: 10.1007/s10147-008-0818-7. [DOI] [PubMed] [Google Scholar]
  42. Yang J., Lin Y., Guo Z., Cheng J., Huang J., Deng L., Liao W., Chen Z., Liu Z., Su B. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol. 2001;2:620–624. doi: 10.1038/89769. [DOI] [PubMed] [Google Scholar]
  43. Zhang P.J., Zhao J., Li H.Y., Man J.H., He K., Zhou T., Pan X., Li A.L., Gong W.L., Jin B.F., et al. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitinproteasome. EMBO J. 2007;26:1831–1842. doi: 10.1038/sj.emboj.7601602. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES